Overview
- Focuses on a state-of-the-art review of early phase clinical trials for cancer immunotherapy
- Discusses about biomarker selection and combinatorial strategies
- Discusses about safety/toxicity determination of Phase 2 dosing, endpoints in the setting of psuedoprogession and histology selection as they relate to early phase cancer immunotherapy
- Features chapters written by internationally-known experts in the field
Part of the book series: Current Cancer Research (CUCR)
Access this book
Tax calculation will be finalised at checkout
Other ways to access
Table of contents (11 chapters)
Keywords
About this book
Editors and Affiliations
About the editors
Razelle Kurzrock, MD, is Senior Deputy Director for Clinical Science, Chief, Division of Hematology & Oncology, Murray Professor of Medicine, Director, Center for Personalized Cancer Therapy & Clinical Trials Office, University of California, San Diego.
Sandip Patel, MD, is Assistant Professor, Cancer Immunotherapy Program, Experimental Therapeutics (Phase 1 Program), Thoracic Oncology, Division of Hematology & Oncology and Center for Personalized Cancer Therapy, UC San Diego Moores Cancer Center.
Bibliographic Information
Book Title: Early Phase Cancer Immunotherapy
Editors: Sandip Pravin Patel, Razelle Kurzrock
Series Title: Current Cancer Research
DOI: https://doi.org/10.1007/978-3-319-63757-0
Publisher: Springer Cham
eBook Packages: Medicine, Medicine (R0)
Copyright Information: Springer International Publishing AG 2018
Hardcover ISBN: 978-3-319-63756-3Published: 10 November 2017
Softcover ISBN: 978-3-319-87628-3Published: 28 August 2018
eBook ISBN: 978-3-319-63757-0Published: 03 November 2017
Series ISSN: 2199-2584
Series E-ISSN: 2199-2592
Edition Number: 1
Number of Pages: XI, 331
Number of Illustrations: 9 b/w illustrations, 15 illustrations in colour
Topics: Cancer Research